ArticleJournal of dental sciences2025
Single-cell isolation reveals 5 fluorouracil-resistant subclones in oral squamous cell carcinoma: New insights into stemness and epithelial-mesenchymal transition for targeted therapies.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dyskerin dysfunction in cancer development: from telomere dysregulation to immune deficiency.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Oral squamous cell carcinoma (OSCC) often recurs and has poor clinical outcomes, partly attributable to subpopulations that develop resistance to 5 fluorouracil (5FU). Elucidating how these resistant clones emerge and drive tumour aggressiveness is essential for improving OSCC treatment approaches. Materials and methods: To establish 5FU-resistant cells, SCC25 cells were repeatedly exposed to 5FU, and single-cell clones were subsequently isolated using a microfluidic system. Three subclones-Holoclone, Meroclone, and Paraclone-were evaluated for their 5FU responses, expression of drug-efflux pumps (ABCB1, ABCG2), and resistance in three-dimensional (3D) cultures. Their levels of cancer stem cell (CSC) markers (OCT4, SOX2, CD44, CD133) and epithelial-mesenchymal transition (EMT) markers (E-cadherin, Vimentin, Twist) were also examined. In addition, Transwell assays were performed to assess migration and invasion. Results: Compared with parental SCC25 cells, the three subclones exhibited markedly higher resistance to 5FU under 3D spheroid conditions, concurrent with upregulated ABCB1 and ABCG2 expression. All three subclones showed enhanced sphere-forming capacity and increased OCT4 and SOX2 levels, consistent with higher proportions of CD44 Conclusion: Extended 5FU treatment in OSCC selects for distinct subclones that exhibit CSC-like traits and EMT-related motility, promoting robust chemoresistance and heightened malignancy. These findings emphasise the importance of developing comprehensive therapeutic strategies that simultaneously target drug-efflux mechanisms, CSC markers, and EMT pathways to more effectively control OSCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.